Jean-Pierre Sommadossi - 31 Jan 2026 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
President, CEO, and Chairman, Director
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi
Issuer symbol
AVIR
Transactions as of
31 Jan 2026
Net transactions value
-$77,834
Form type
4
Filing time
03 Feb 2026, 19:46:07 UTC
Previous filing
04 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sommadossi Jean-Pierre President, CEO, and Chairman, Director 225 FRANKLIN STREET, SUITE 2100, BOSTON /s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi 03 Feb 2026 0001296995

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVIR Common Stock Options Exercise +272,983 +91% 573,923 31 Jan 2026 Direct F1
transaction AVIR Common Stock Tax liability $449,834 -106,093 -18% $4.24 467,830 31 Jan 2026 Direct
transaction AVIR Common Stock Options Exercise $372,000 +300,000 +64% $1.24 767,830 03 Feb 2026 Direct
holding AVIR Common Stock 5,866,025 31 Jan 2026 Held by JPM Partners LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Options Exercise $0 -173,466 -100% $0.000000 0 31 Jan 2026 Common Stock 173,466 Direct F1, F2
transaction AVIR Restricted Stock Units Options Exercise $0 -99,517 -100% $0.000000 0 31 Jan 2026 Common Stock 99,517 Direct F1, F3, F4
transaction AVIR Stock Option (Right to Buy) Options Exercise $0 -300,000 -100% $0.000000 0 03 Feb 2026 Common Stock 300,000 $1.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
F3 Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
F4 Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026.
F5 The option is fully vested and exercisable.